# MCI Capital – occasions favor the prepared

After a difficult first quarter of 2022 for the company, the second quarter proved equally challenging, especially for the MCI.TV FIZ subfund. In the end, the company managed to minimize its net loss to zero in the first half of the year, thanks to the upward revaluation of the bargain eSky stake acquired. The company's performance in the coming quarters in part will depend on the stock market, as the quotations of comparable companies affect the valuations of portfolio positions. After updating our forecasts, w are adjusting our valuation of MCI Capital's shares from PLN 33.1 to PLN 29.6 mainly due to the peers devaluation. The discount in the stock' valuation to NAV is ca. 53% compared to ca. 21% for peers.

## 1H22 results influenced by market downturn and situation in the East

In terms of the entire first half of 2022, losses on investments decreased to PLN -13.5m, EBIT decreased to PLN -20.8m, and net income amounted to PLN -1.1m. The result for the first half of the year consisted of a positive result on MCI.EuroVentures FIZ (PLN +131.2m), including upward revaluation of the investment in eSky (PLN +163m) and a negative result on MCI.TechVentures FIZ (PLN -128.5m), including revaluation of Morele Group (PLN -47m), Gett (PLN -34m), Answear (PLN -24m) and Travelata (PLN -21m). Net debt, according to our estimates, at the end of 2Q22 was around PLN 162m (PLN 218m after adjusting for the dividend liability and MCI.TV's rate of return guarantee) vs. PLN 196m at the end of 1Q22.

## Liquidity at PLN 777 million creates opportunity for bargain buying

The Group's liquidity at the end of 1H2022 was about PLN 777m, of which MCI Capital is a one of the leading private about PLN 400 million is cash and cash equivalents placed in the MCI.EV FIZ Subfund (and indirectly in MCI.CV) and available credit lines of nearly PLN 300m. Management indicates that the current stock market downturn favors buyers, and expects even more attractive valuations in 2023. The eSky stake acquired in 2022 is one of this year's successful investments.

## **Risks for our forecasts and valuation**

Main risk factors for our valuation are limited portfolio liquidity, high concentration of portfolio investments and the adopted valuation method for certain portfolio companies.

## Our valuation is equally based on NAV (PLN33.1/share) and peers valuation to the other PE funds (PLN26.0/share) and indicates present fair price at PLN29.6/share.


PLN m	2020	2021	2022P	2023P
Investment profits	162	380	0	98
Net profit	134	465	-21	77
NAV/share	27.1	35.2	33.4	34.2
P/E (x)	7.2	2.1	na	12.4
P/NAV (%)	69%	53%	56%	55%

Source: MCI Capital ASI (2020-21), Noble Securities (2022F-2023F)

The preparation of report was finalized on 07/10/2022 at 10:10 a.m.. The first publication took place on 07/10/2022 at 10:15 a.m



Ш		
es	Current price	16,1 zł
'e	Valuation	29.6 zł
:0 's	Upside/downside	84%
	Market cap.	PLN 842m
	Free float	22%
0	Avg. Vol. 6M	3 082



## **COMPANY PROFILE**

equity fund in Central-Eastern Europe. Since 1999 group realised over 100 investment projects and finished over 58 exits. Assets under management are estimated over PLN 2B.

## **SHAREHOLDERS**

Tomasz Czechowicz	77.85%
Others	22.15%

Krzysztof Radojewski

**Deputy Head of Research and Advisory** Department

krzysztof.radojewski@noblesecurities.pl +48 22 213 22 35



## VALUATION

We calculated the value of one share of MCI Capital using Net Asset Value (NAV) method on the basis of book value of investment portfolio at the end of 2022 and peers valuation to the other few European PE companies. We give both methods equal weights (methodology unchanged).

In table below we present valuation summary:

Valuation summary	Weight (x)	Per share (PLN)	Previously (PLN)	change %
Net asset value (NAV)	0.50	33.1	33.4	-1%
Peers	0.50	26.0	32.8	-21%
Average valuation		29.6	33.1	-11%
Current price		16.1	19.0	-16%
Upside/downside		84%	74%	
Source: Noble Securities	4			

Source: Noble Securities

## **PEER VALUATION**

We value the assets held by MCI Capital at book value, which should reflect fair value. It is worth noting that the discount in the company's market valuation relative to book value has narrowed in recent quarters relative to peers. In our previous report, the P/BV ratio for peers was 0.98x and for MCI 0.56x (MCI's valuation discount to the peer group at 43%), and now peers are valued at P/BV 0.79x and MCI 0.48x (MCI's valuation discount to the peer group has fallen to 38%). It seems that one of the contributing factors is the dividend policy introduced. The P/BV valuation ratios of selected European PE companies are shown below. The main difference between these companies and MCI Capital is their higher market capitalization. Based on the valuation ratios of European PE companies, we value the company using the comparative method at PLN 26.0 per share (previously PLN 32.8).

Company	Currency	Market cap (PLN m)	P/BV (x) 2021	Div. yield
3I GROUP PLC	PLN	61 203	0.85	3.6%
GIMV NV	PLN	5 970	0.85	5.6%
EURAZEO	PLN	21 804	0.70	3.2%
DEUTSCHE BETEILIGUNGS AG	PLN	2 126	0.74	5.1%
Mean			0.79	
MCI Capital	PLN	842	0.48	4.4%
Premium/discount to mean (%)			-38%	
Implied fair value of MCI Capital	PLN		26.0	
Implied fair value of MCI Capital	PLN		26.0	

Source: Bloomberg, Noble Securities, data on 07/10/2022 at 8:51 a.m.

## Exchange's Analitical Coverage Support Programme



P&L (PLN m)	2021	2022F	2023F	2024F
Investment management fees	31	15	15	15
Investment profits	380	0	98	99
Operating expenses	41	37	37	37
Other operating revenues and expenses	0	0	0	0
EBIT	358	-12	86	87
Net financial income and expenses	-11	-26	-26	-26
Profit before taxation	346	-38	60	61
Income tax	119	38	0	0
Net profit	465	0	60	61

Source: MCI Capital ASI (2021), Noble Securities (forecasts, 2022F-2024F)

Balance sheet (PLN m)	2021	2022F	2023F	2024F
Assets	2 064	2 028	2 051	2 076
Non-current assets	2 014	1 969	1 987	1 975
Investment certificates	2 009	1 964	1 982	1 970
Other non-current assets	5	5	5	5
Current assets	50	59	64	100
Cash and cash equivalents	21	52	57	94
Other current assets	29	7	7	7
Liabilities	2 064	2 028	2 052	2 076
Equity	1 808	1 772	1 796	1 820
Non-current liabilities	137	137	137	137
Liabilities on bonds	110	110	110	110
Deferred tax liabilities	11	11	11	11
Others	16	16	16	16
Current liabilities	119	119	119	119
Liabilities on bonds	17	17	17	17
Liabilities on bills of exchange	66	66	66	66
Other	36	36	36	36

Source: MCI Capital ASI (2021), Noble Securities (forecasts, 2022F-2024F)

Cash flow (PLN m)	2021	2022F	2023F	2024F
CF from operating activities	79	93	68	99
CF from investment activities	-2	0	0	0
CF from financial activities	-95	-61	-62	-62
CF	-18	32	5	36
Cash at the beginning of the period	39	21	52	57
Cash at the end of the period	21	52	57	94

Source: MCI Capital ASI (2021), Noble Securities (forecasts, 2022F-2024F)

Selected indicators	2021	2022F	2023F	2024F
Book value per share	34.47	33.14	33.57	34.03
Dividend per share	0.53	0.7	0.7	0.7
Net debt	172	141	136	99
Net debt/BV	10%	8%	8%	5%
Number of shares issued	52.5	53.5	53.5	53.5
P/BV	0.45	0.47	0.46	0.46

Source: MCI Capital ASI (2021), Noble Securities (forecasts, 2022F-2024F)



#### LEGAL DISCLAIMER

#### FUNDAMENTAL RULES FOR ISSUING ANALYTICAL REPORT

This analytical report, hereinafter referred to as the "Report", was prepared by Noble Securities S.A. ("NS") based in Warsaw.

The basis for the preparation of the Report were publicly available information known to the Analyst as at the date of preparing the Report, in particular information provided by the Issuer in current and periodic reports prepared as part of its disclosure obligations.

The Report only expresses the analyst's knowledge and views as at the date of its preparation.

The forecasts and evaluation elements presented in the Report are based solely on the analysis performed by the Analyst, without arrangements with the Issuer or with other entities, and are based on a number of assumptions that may turn out to be irrelevant in the future.

NS or the Analyst do not give any assurance that the forecasts will work.

The report issued by NS is valid for a period of 24 months, unless it is previously updated. The frequency of updates results from the date of publication by the Issuer of financial results for a given reporting period, the market situation or subjective assessment of the Analyst.

### STRONG AND WEAKNESSES OF VALUATION METHODS APPLIED BY NS IN THE REPORT

The DCF (eng. discounted cash flow) method - is considered the methodologically most appropriate valuation technique and consists in discounting financial flows generated by the rated entity. Strengths of this method include taking into account all cash flows that flow in and out of the company and the cost of money over time. The disadvantages of the DCF valuation method are: a large number of assumptions and parameters that need to be estimated and the sensitivity of valuation to changes in these factors. A variation of this method is the discounted dividend method.

**Peers valuation** - is based on a comparison of valuation multipliers of companies in the industry in which the rated entity operates. This method very well reflects the current state of the market, requires fewer assumptions and is simpler to apply (relatively high availability of indicators for compared entities). Its disadvantages include high volatility related to price fluctuations and stock exchange indices (in the case of comparison to listed companies), subjectivism in the selection of a group of comparable companies and simplification of the company image leading to the omission of some important parameters (eg growth rate, corporate governance, non-operational assets, differences in accounting standards).

### INTERESTS OR CONFLICTS OF INTERESTS THAT MAY AFFECT THE REPORTING OBJECTIVITY OF THE REPORT

#### The report was prepared by NS for consideration, on behalf of the Warsaw Stock Exchange S.A.

The Analyst is not a party to any contract concluded with the Issuer and does not receive remuneration from the Issuer. The Analyst's remuneration for preparing the Report due from NS is not directly related to transactions in brokerage services provided by NS or other types of transactions carried out by NS or any other legal entity that is part of the group to which NS belongs or with transaction fees that they receive NS or these people. It can not be ruled out that the remuneration that may be due in future to a NS Analyst by another title may be indirectly dependent on NS financial results, including those obtained as part of investment banking transactions related to the Issuer's financial instruments. The Analyst is not a party to any contract concluded with the Issuer and does not receive remuneration from the Issuer. The Analyst's remuneration for preparing the Report due from NS is not directly related to transactions in brokerage services provided by NS or other types of transactions carried out by NS or any other legal entity that is part of the group to which NS belongs or with transactions in brokerage services provided by NS or other types of transactions carried out by NS or any other legal entity that is part of the group to which NS belongs or with transaction fees that they receive NS or these people. It can not be ruled out that the remuneration that may be due in future to a NS Analyst by another title may be indirectly dependent on NS financial results, including those obtained as part of the group to which NS belongs or with transaction fees that they receive NS or these people. It can not be ruled out that the remuneration that may be due in future to a NS Analyst by another title may be indirectly dependent on NS financial results, including those obtained as part of investment banking transactions related to the Issuer's financial instruments.

It is possible that NS has or will have the intention to submit an offer to provide services to the Issuer.

NS is or has been within 12 months a party to agreements with the Issuer concerning provision of brokerage services.

NS has offered financial instruments of the Issuer in the last 12 months.

- NS is or has been within 12 months a party to agreements with the Issuer's Parent Company concerning provision of brokerage services.
- NS acts as a market maker in relation to financial instruments of the Issuer's Parent Company.

NS within last 12 months offered financial instruments of Parent to Issuer.

#### ORGANIZATIONAL AND ADMINISTRATIVE SOLUTIONS AND INFORMATION BARRIERS ESTABLISHED TO PREVENT CONFLICT OF INTERESTS AND TO AVOID THEMSELVES

Detailed rules of conduct in the event of conflicts of interest are set out in the "Regulations of Conflicts of Interest Management at Noble Securities SA" available at the website www.noblesecurities.pl in the tab: "About us" / "Regulations" / "Information policy".

The internal structure of NS ensures organizational separation of analysts from individuals (teams) performing activities that involve the risk of a conflict of interest and prevents conflicts of interest, and in the event of such conflict enables protection of the Client's interests against the harmful effects of this conflict. In particular, Analysts do not have access to information about transactions concluded on the NS's own account and to Client orders. NS ensures that there is no possibility for third parties to exert any adverse influence on the performance of the work by Analysts. NS ensures that there are no links between the amount of remuneration of employees of one organizational unit and the amount of remuneration of employees of another organizational unit, or the amount of income earned by that other organizational unit, if these units perform activities that involve the risk of a conflict of interests

NS has implemented internal regulations regarding the flow of confidential and professional information, which is aimed at securing confidential information or professional secrecy and preventing its unjustified flow or misuse. NS limits to a minimum the circle of people who have access to confidential information or professional secrecy. In order to control access to relevant non-public information, within NS there are internal limitations and barriers in the transfer of information, so-called *Chinese walls*, i.e. rules, procedures and physical solutions to prevent the flow and use of confidential information and constitute professional secrecy. NS uses restrictions in physical access (separate rooms, lockable filling cabinets) and in access to information systems.

NS has implemented regulations in the scope of performing activities consisting in preparing investment analyzes, financial analyzes and other general recommendations regarding transactions in financial instruments, as well as the internal procedure regulating the subject scope. NS discloses in the content of Reports prepared by itself all connections and circumstances that could affect the objectivity of the Reports being prepared. It is forbidden to accept material or non-material benefits by NS or the Analyst from entities having a significant interest in the content of the Report, suggesting to the Issuer by NS or Analyst content favorable to that Issuer. It is forbidden to make available to the Issuer or other persons than Analysts, the Report, containing the content of the recommendation or the target price, before commencing its distribution for purposes other than verification of the NS's compliance with its legal obligations.

NS has implemented internal regulations regarding the rules of concluding personal transactions by involved persons, including prohibits the use of information obtained in connection with business activities for personal transactions. In addition, Analysts may not enter into personal transactions regarding the Issuer's financial instruments or related financial instruments prior to the dissemination of the Report, as well as personal transactions that conflict with the content of the Report and when NS starts or works on issuing Issuer's financial instruments since the Insurer's information in in this respect until the prospectus is published - in the case of a public offer or for launching an offer.

#### OTHER INFORMATION AND RESERVATIONS

NS ensures that the Report has been prepared with due diligence and integrity based on generally available facts and information recognized by the Analyst as reliable, reliable and objective, however NS nor the Analyst does not guarantee that they are fully accurate and complete. If the Report indicates the addresses of the websites used in the preparation of the Report, neither the Analyst nor NS takes responsibility for the content of these websites.

Investing can involve high investment risk. The analytical report cannot be treated as an assurance or guarantee of avoiding losses, or achieving potential or expected results, in particular profits or other benefits from transactions carried out on its basis, or in connection with refraining from such transactions. A general description of financial instruments and the risk related to investing in individual financial instruments is presented at www.noblesecurities.pl in the tab Brokerage House / Brokerage Account/ Documents. NS points out that although the above information has been prepared with due diligence, in particular in a reliable manner and in accordance with NS's best knowledge, it may not be exhaustive and may exist or be updated in the specific situation in which an investor is or will be located other risk factors than those indicated in the above information by NS. The investor should bear in mind that investments in individual financial instruments may result in the loss of some or all of the funds invested, and even involve the additional costs.

Investors using the Report may not resign from independent assessment and take into account other circumstances than indicated by the Analyst or by NS.



The Report has been prepared in accordance with legal requirements ensuring independence, in particular from the Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards concerning technical means for the purpose of presenting investment recommendations or other information recommending or suggesting an investment strategy and disclosing particular interests or indications of conflicts of interest. The report is an investment study referred to in art. 36 par. 1 Commission Delegated Regulation (EU) 2017/565 of 25 April 2016 supplementing Directive 2014/65 / EU of the European Parliament and of the Council with regard to organizational requirements and operating conditions for investment firms and concepts defined for the purposes of this directive.

#### The Report or any of its entries do not state:

- offer within the meaning of art. 66 of the Act of 23 April 1964 the Civil Code,
- grounds for concluding a contract or creating a liability,
- public offering of financial instruments within the meaning of art. 3 of the Act of July 29, 2005 on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies,
- invitations to subscribe for or purchase securities of the Issuer,
- investment advisory services or portfolio management services referred to in the Act of 29 July 2005 on Trading in Financial Instruments,
- investment, legal, accounting or other types of advice.

#### The Report

- is published on the NS website: https://noblesecurities.pl/dom-maklerski/analizy2/program-wsparcia-pokrycia-analitycznego-gpw/1794-mci-capital-s-a,
- is intended for distribution only on the territory of the Republic of Poland, and is not intended for distribution or transmission, directly or indirectly, in the United States of America, Canada, Japan or Australia, or any other jurisdiction, where such distribution would violate relevant provisions of the given jurisdiction or required registration in that jurisdiction,
- does not contain all information about the Issuer and does not allow full assessment of the Issuer, in particular as regards the Issuer's financial situation, because only certain data regarding the Issuer were selected for the Report,
- is for information purposes only, so it is not possible to comprehensively evaluate the Issuer based on the Report.

#### FINAL REMARKS

Analyst preparing the Report: Krzysztof Radojewski

Date and time of completion of the Report: 07/10/2022 at 10.10 a.m.. Date and time of the first dissemination of the Report: 07/10/2022 at 10.15 a.m..

The proprietary copyrights to the Report are held by the Stock Exchange in Warsaw S.A. Dissemination or reproduction of the Report (in whole or in any part) without the written consent of the Warsaw Stock Exchange S.A. is forbidden.

NS is subject to the supervision of the Polish Financial Supervision Authority.

Recent research concerning MCI Capital S.A.							
Direction	na	na.	na.	na.	na.	na.	na.
Date	02/05/2022 at. 8:30 a.m.	10/07/2021 at 8:20 a.m.	05/14/2021 at 10:19 a.m.	11/12/2019 at 11:50 a.m.	30/06/2020 at 5:20 p.m.	12/03/2020 at 4:08 p.m.	28.06.2019 at 2:55 p.m.
Stock price at the date of report	19.0	22.5	19.2	15.0	12.1	8.3	7.3
Valuation per share	33.1	41.2	30.9	30.4	24.9	21.9	26.5
WIG Index at the date of report	57 754.98	71 789.34	62 004.52	56 230.40	49 569.17	37 164.02	60187.43



## All recommendations distributed by NS in last 12 months:

Company	Direction	Target price	Price at publication	Current price	Difference to price target	Date of publication (1)	Validity date (2)	Prepared by (3)
Bioton	na	4,7	3,8	3,63	29%	06.09.2022	24m	Krzysztof Radojewski
Dino Polska	Reduce	286,8	351,5	310,00	-7%	10.08.2022	9M	Dariusz Dadej
Eurocash	Accumulate	13,0	12,1	11,89	9%	10.08.2022	9M	Dariusz Dadej
Amica	Hold	69,7	71,4	67,30	4%	05.08.2022	9M	Michał Sztabler
Wielton	Reduce	4,9	5,5	6,08	-19%	12.07.2022	9M	Michał Sztabler
Krynicki Recykling	na	20,9	22,6	22,70	-8%	04.07.2022	24M	Dariusz Dadej
Captor Therapeutics	Buy	163,0	116,0	138,00	18%	28.06.2022	9M	Krzysztof Radojewski
Celon Pharma	Buy	29,3	14,9	12,74	130%	28.06.2022	9M	Krzysztof Radojewski
Molecure	Buy	21,7	13,2	13,90	56%	28.06.2022	9M	Krzysztof Radojewski
Ryvu Therapeutics	Buy	51,8	23,5	35,95	44%	28.06.2022	9M	Krzysztof Radojewski
CD Projekt	Sell	74,1	94,4	110,26	-33%	24.06.2022	9M	Maciej Kietliński
Ten Square Games	Sell	98,6	117,0	104,60	-6%	24.06.2022	9M	Maciej Kietliński
Apator	Reduce	12,2	14,8	13,62	-10%	06.06.2022	9M	Michał Sztabler
Aplisens	na	16,0	14,1	13,40	19%	06.06.2022	24M	Michał Sztabler
Sonel	na	10,2	9,8	9,60	6%	06.06.2022	24M	Michał Sztabler
TIM	na	54,3	31,4	25,80	110%	06.06.2022	24M	Michał Sztabler
11 bit studios	Buy	626,0	502,0	513,00	22%	18.05.2022	9M	Maciej Kietliński
Forte	Accumulate	38,9	33,0	23,80	63%	13.05.2022	9M	Dariusz Dadej
MCI Capital	na	33,1	19,0	16,05	106%	02.05.2022	24M	Krzysztof Radojewski
Bioton	na	7,2	4,1	3,63	97%	19.04.2022	24M	Krzysztof Radojewski
Selvita	Buy	96,2	78,5	88,40	9%	08.04.2022	9M	Krzysztof Radojewski
Mobruk	Buy	500,9	398,0	300,50	67%	07.04.2022	9M	Dariusz Dadej
Artifex Mundi	Buy	13,2	10,1	6,14	115%	28.03.2022	9M	Maciej Kietliński
Celon Pharma	Buy	42,2	24,8	12,74	231%	16.03.2022	9M	Krzysztof Radojewski
Creepy Jar	Buy	812,0	700,0	600,00	35%	15.03.2022	9M	Maciej Kietliński
LW Bogdanka	Hold	57,9	55,6	33,54	72%	11.03.2022	9M	Michał Sztabler
Tauron PE	Buy	3,5	2,7	2,11	68%	10.03.2022	9M	Michał Sztabler
Ailleron	na	19,1	11,4	11,95	60%	03.03.2022	24M	Dariusz Dadej
BoomBit	Buy	22,9	18,3	9,56	140%	04.02.2022	9M	Maciej Kietliński
Krynicki Recykling	na	31,8	19,6			05.01.2022	24M	Dariusz Dadej
Sonel	na	11,8	10,6			22.12.2021	24M	Michał Sztabler
CD Projekt	Reduce	176,4	193,0			21.12.2021	9M	Maciej Kietliński
Dino Polska	Reduce	295,0	338,0			03.12.2021	9M	Dariusz Dadej
Eurocash	Accumulate	12,2	10,9			03.12.2021	9M	Dariusz Dadej
Apator	Hold	19,1	18,7			29.11.2021	9M	Michał Sztabler
OncoArendi	Buy	48,1	38,4			16.11.2021	9M	Krzysztof Radojewski
Amica	Accumulate	157,6	131,6			18.10.2021	9M	Michał Sztabler
Ten Square Games	Buy	549,3	382,6			18.10.2021	9M	Maciej Kietliński
TIM	na	62,3	42,6			14.10.2021	24M	Michał Sztabler
Forte	Hold	51,5	53,5			11.10.2021	9M	Dariusz Dadej
MCI Capital	na	41,2	22,5			07.10.2021	24M	Krzysztof Radojewski

(1) Date of publication is simultaneously date of first publication,

(2) recommendation is valid for a period of 9 months, unless it is previously updated,

(3) Job position: Krzysztof Radojewski – Deputy Head of Research and Advisory Department, Michał Sztabler – Equity Analyst, Dariusz Dadej - Equity Analyst, Maciej Kietliński - ended his work in NS on 06/30/2022



## MARKET RESEARCH DEPARTMENT

### Sobiesław Kozłowski, MPW

sobieslaw.kozlowski@noblesecurities.pl tel: +48 22 213 22 39 model portfolios

Krzysztof Radojewski krzysztof.radojewski@noblesecurities.pl biotechnology

### Michał Sztabler

michal.sztabler@noblesecurities.pl tel: +48 22 213 22 36 industrials, utillities, mining

## Dariusz Dadej

dariusz.dadej@noblesecurities.pl tel: +48 22 660 24 83 retail, industrials

## Krzysztof Ojczyk, MPW

krzysztof.ojczyk@noblesecurities.pl tel: +48 12 422 31 00 technical analysis

